A few readers of this board profitably shorted IDIX at the height of the HCV M&A frenzy. It was a pretty good bet that the M&A lightning would not strike a third time, particularly given the encumbered nature of IDIX’s assets at that time.
The IDIX experience suggests a rule of thumb to guide investors: There are many copycat M&A deals that sport seemingly exorbitant price premiums (not just in biotech), but there are not many cases where it happens a third time in the same industry within a short time.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.